Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Macroprolactinomas and epilepsy.

Doddabele Deepak1, Christina Daousi, Mohsen Javadpour

  • 1Diabetes and Endocrinology Clinical Research Group, University Hospital Aintree, Liverpool, UK.

Clinical Endocrinology
|March 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome predictors in older adults (≥ 65 years) with aneurysmal subarachnoid haemorrhage.

Neurosurgical review·2026
Same author

Early analysis of data from the British & Irish Brain Arteriovenous Malformations Registry (BIBAR).

Brain & spine·2025
Same author

Core Outcome Sets for Meningioma In Clinical studies (COSMIC): An international patient and healthcare professional consensus for research studies.

Neuro-oncology practice·2025
Same author

Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours.

BMJ case reports·2025
Same author

Preliminary Experience with the use of a 3-Dimensional Exoscope for Excision of Unruptured Brain Arteriovenous Malformations: Case Series and Comparative Analysis.

World neurosurgery·2025
Same author

Intra-operative neurophysiological monitoring as an adjunct to resection of eloquent cerebral arteriovenous malformations: a retrospective cohort study.

British journal of neurosurgery·2025
Same journal

Supraphysiological Glucocorticoid Doses and Pitfalls of Annual Biomarker Monitoring in Adults With CAH.

Clinical endocrinology·2026
Same journal

Subacute Thyroiditis in Denmark: A Nationwide Study of 1763 Cases.

Clinical endocrinology·2026
Same journal

Pubertal Dynamics of Sertoli and Leydig Cell Dysfunction in Klinefelter Syndrome.

Clinical endocrinology·2026
Same journal

Regarding Non-Classical Presentations of Rare Hereditary Hypoparathyroidism: A Case Series of CASR, GNA11, and GATA3 Mutations in Parathyroidology.

Clinical endocrinology·2026
Same journal

Dual Metabolic Burden of Polyendocrine Metabolic Ovarian Syndrome (PMOS) and Gestational Diabetes in Pregnancy: Impact on Neonatal Anthropometry: Insights From the Born in Bradford Cohort.

Clinical endocrinology·2026
Same journal

Preoperative CALLY Index for Identifying Atypical Parathyroid Tumors.

Clinical endocrinology·2026
See all related articles

Epilepsy is common in patients with invasive macroprolactinomas, often presenting as temporal lobe seizures. Dopamine agonist therapy effectively reduces seizure frequency and can lead to complete remission.

Area of Science:

  • Neuroendocrinology
  • Neurology
  • Oncology

Background:

  • Macroprolactinomas, a type of pituitary tumor, can cause neurological symptoms due to mass effect.
  • Epilepsy is a neurological disorder characterized by recurrent seizures.
  • The relationship between macroprolactinomas and epilepsy requires further investigation.

Purpose of the Study:

  • To determine the prevalence and characteristics of epilepsy in patients diagnosed with macroprolactinomas.
  • To evaluate the effectiveness of dopamine agonist (DA) therapy in managing epilepsy associated with macroprolactinomas.

Main Methods:

  • A retrospective case note analysis was conducted on patients with macroprolactinoma diagnosed between 1996 and 2006.
  • Detailed examination of patients with epilepsy at the time of macroprolactinoma diagnosis.

Related Experiment Videos

  • Cranial imaging and prolactin level assessment were performed.

    • Main Results:

    • Six out of 64 (9.4%) macroprolactinoma patients had epilepsy, all with invasive tumors and hyperprolactinemia.
    • Five patients presented with features suggestive of temporal lobe epilepsy.
    • Dopamine agonist therapy led to a rapid reduction in seizure frequency, with four patients achieving complete seizure freedom.

    Conclusions:

    • Invasive macroprolactinomas are frequently associated with epilepsy, particularly temporal lobe epilepsy.
    • Promptly inquiring about seizure history is crucial for diagnosing potentially long-standing epilepsy.
    • Dopamine agonist therapy is effective in managing epilepsy in these patients, potentially reducing anti-epileptic drug requirements and achieving seizure freedom.